Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study

Trial Profile

Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 04 Nov 2009 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 04 Nov 2009 Actual patient number (3021) added as reported by ClinicalTrials.gov.
    • 04 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top